On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health Canada. and approved the COVID-19 Clinical Trial Application for apabetalone.

The planned Phase 2 trial was an open-label study evaluating the safety and efficacy of oral apabetalone, in combination with standard of care for patients hospitalized with COVID-19.